Artwork

Content provided by Audioboom and Pharmaceutical Executive Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Pharmaceutical Executive Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The Weight-Loss Gold Rush: Legal and Regulatory Implications

17:10
 
Share
 

Manage episode 428347348 series 2084987
Content provided by Audioboom and Pharmaceutical Executive Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Pharmaceutical Executive Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
  • Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
  • How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
  • What needs to be done for GLP-1s to be covered
  • Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
  • Advice for investors and financiers who are considering entering the weight-loss medication market
  continue reading

168 episodes

Artwork
iconShare
 
Manage episode 428347348 series 2084987
Content provided by Audioboom and Pharmaceutical Executive Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Pharmaceutical Executive Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
  • Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
  • How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
  • What needs to be done for GLP-1s to be covered
  • Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
  • Advice for investors and financiers who are considering entering the weight-loss medication market
  continue reading

168 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide